Redeye initiates coverage of Guard Therapeutics, a clinical-stage biotech developing innovative therapies for diseases with high unmet needs, focusing on kidney protection at different events of stress. The company is nearing a decisive readout in its phase IIb POINTER study, evaluating RMC-035 as a renal protective agent during cardiac surgery, expected in Q4 2025e. While facing a binary event, we believe the modest valuation offers an asymmetric risk/reward opportunity.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/